H.C. Wainwright reiterates a Buy rating on Iovance Biotherapeutics (IOVA) with a $20 price target after the company announced real-world, retrospective data from patients treated with commercial Amtagvi. The drug demonstrated “impressive” clinical responses, particularly in earlier stage patients, the analyst tells investors in a research note. The firm points out that among 41 evaluable patients treated at four authorized treatment centers, the physician-assessed objective response rate was 48.8%. It believes Amtagvi is working as intended, and even exceeding expectations in less heavily treated patients, post commercialization.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics announces real-world study data on Amtagvi
- Iovance Biotherapeutics Advances Phase 3 Study in Melanoma Treatment
- Iovance Biotherapeutics’ Lifileucel-Pembrolizumab Study: A Potential Game-Changer in Melanoma Treatment
- Iovance Biotherapeutics CFO Resignation and Interim Appointment
- Iovance Biotherapeutics Advances in Melanoma Treatment with Lifileucel-Pembrolizumab Study